Advances in Newly Diagnosed Multiple Myeloma: The Impact of More Intensive Therapy on Clinical Outcomes

Experts discuss therapeutic advances for newly diagnosed multiple myeloma and elaborate on the impact and availability of more intensive therapies on clinical outcomes.

Share

Program Content

Activities

CD38 in MM
Rationale for Targeting CD38, Disparities in Care, and Treatment Implications in Newly Diagnosed MM
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2024

Expires: June 09, 2025

Quad Tx in ASCT Eligible NDMM
The Impact of Quadruplet Therapy Incorporating CD38 Antibodies in Transplant-Eligible Patients With NDMM
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2024

Expires: June 10, 2025

CD38 mAb in ASCT Ineligible NDMM
Optimizing Clinical Outcomes With CD38 Antibodies for Transplant-Ineligible Patients With NDMM
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2024

Expires: June 10, 2025

Faculty

cover img faculity

Michele Cavo, MD

Head, “Seràgnoli” Institute of Hematology
Director, Postgraduate Residency in Hematology
Full Professor of Hematology
Department of Medical and Surgical Sciences
Bologna University School of Medicine
Bologna, Italy

cover img faculity

Francesca Gay, MD, PhD

Associate Professor
Department of Molecular Biotechnology and Health Science
University of Torino
SC Ematologia 1
AOU Citta della Salute e della Scienza
Torino, Italy

cover img faculity

Paul G. Richardson, MD

Director of Clinical Research
Clinical Program Leader
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Sanofi.

Sanofi